
Jason Chia-Hsien Cheng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3356612/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Longitudinal shear wave elasticity measurements of millimeter-sized biomaterials using a single-element transducer platform. PLoS ONE, 2022, 17, e0266235.	2.5	2
2	Tumor-Derived C-C Motif Ligand 2 Induces the Recruitment and Polarization of Tumor-Associated Macrophages and Increases the Metastatic Potential of Bladder Cancer Cells in the Postirradiated Microenvironment. International Journal of Radiation Oncology Biology Physics, 2022, 114, 321-333.	0.8	12
3	Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial. Neuro-Oncology, 2021, 23, 478-486.	1.2	33
4	Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival and Liver Toxicity in Patients With Hepatocellular Carcinoma Treated With Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 474-484.	0.8	10
5	Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe. Frontiers in Oncology, 2021, 11, 646473.	2.8	3
6	CT-Based Collision Prediction Software for External-Beam Radiation Therapy. Frontiers in Oncology, 2021, 11, 617007.	2.8	2
7	Randomized multi-reader evaluation of automated detection and segmentation of brain tumors in stereotactic radiosurgery with deep neural networks. Neuro-Oncology, 2021, 23, 1560-1568.	1.2	26
8	Outcomes and Prediction Models for Exclusive Prostate Bed Salvage Radiotherapy among Patients with Biochemical Recurrence after Radical Prostatectomy. Cancers, 2021, 13, 2672.	3.7	4
9	Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis. Journal of Neuro-Oncology, 2021, 153, 455-465.	2.9	1
10	In Reply to Cousins et al. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1252-1253.	0.8	0
11	Using Megavoltage Computed Tomography to Estimate Radiotherapy Dose for High-Density Metallic Implants. IEEE Transactions on Instrumentation and Measurement, 2021, 70, 1-11.	4.7	0
12	Circulating Exosomal Integrin β3 Is Associated with Intracranial Failure and Survival in Lung Cancer Patients Receiving Cranial Irradiation for Brain Metastases: A Prospective Observational Study. Cancers, 2021, 13, 380.	3.7	11
13	A retrospective study of clinicopathologic and molecular features of inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Journal of the Formosan Medical Association, 2021, 120, 2176-2185.	1.7	2
14	Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy. Frontiers in Oncology, 2021, 11, 730646.	2.8	1
15	Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy. Liver Cancer, 2020, 9, 326-337.	7.7	11
16	Enhanced Radiosensitization for Cancer Treatment with Gold Nanoparticles through Sonoporation. International Journal of Molecular Sciences, 2020, 21, 8370.	4.1	10
17	Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells. Radiation Oncology, 2020, 15, 58.	2.7	6
18	Impact of breath-hold level on positional error aligned by stent/Lipiodol in Hepatobiliary radiotherapy with breath-hold respiratory control. BMC Cancer, 2020, 20, 613.	2.6	2

JASON CHIA-HSIEN CHENG

#	Article	IF	CITATIONS
19	Lower postoperative natural killer cell activity is associated with positive surgical margins after radical prostatectomy. Journal of the Formosan Medical Association, 2020, 119, 1673-1683.	1.7	8
20	Circular RNA TUBD1 Acts as the miR-146a-5p Sponge to Affect the Viability and Pro-Inflammatory Cytokine Production of LX-2 Cells through the TLR4 Pathway. Radiation Research, 2020, 193, 383.	1.5	19
21	Efforts to Reduce the Impact of Coronavirus Disease 2019 Outbreak on Radiation Oncology in Taiwan. Advances in Radiation Oncology, 2020, 5, 534-537.	1.2	14
22	An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. Radiotherapy and Oncology, 2020, 148, 73-81.	0.6	23
23	<i>C1QTNF6</i> as a Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma. DNA and Cell Biology, 2020, 39, 1000-1011.	1.9	13
24	Risk Factors and Genetic Biomarkers of Multiple Primary Cancers in Esophageal Cancer Patients. Frontiers in Oncology, 2020, 10, 585621.	2.8	3
25	Proteomic Profiling of Human Hepatic Stellate Cell Line LX2 Responses to Irradiation and TGF-β1. Journal of Proteome Research, 2019, 18, 508-521.	3.7	17
26	Contactless Monitoring of Pulse Rate and Eye Movement for Uveal Melanoma Patients Undergoing Radiation Therapy. IEEE Transactions on Instrumentation and Measurement, 2019, 68, 474-482.	4.7	7
27	MicroRNA-146a-5p Attenuates Fibrosis-related Molecules in Irradiated and TGF-beta1-Treated Human Hepatic Stellate Cells by Regulating PTPRA-SRC Signaling. Radiation Research, 2019, 192, 621.	1.5	18
28	Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment. European Journal of Surgical Oncology, 2019, 45, 1498-1504.	1.0	9
29	Local Control and Clinical Outcome of High-risk Pediatric Neuroblastoma Patients After Receiving Multimodality Treatment and Helical Tomotherapy. Anticancer Research, 2019, 39, 2207-2215.	1.1	3
30	Radiosensitization in Cancer Treatment with Gold nanoparticles through Synergistic Sonoporation. , 2019, , .		0
31	Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Journal of the Formosan Medical Association, 2019, 118, 1024-1030.	1.7	5
32	Evolving development of multi-parametric normal tissue complication probability model for liver radiotherapy. Translational Cancer Research, 2019, 8, S120-S123.	1.0	0
33	Targeting histone deacetylase 4/ubiquitinâ€conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice. Hepatology, 2018, 67, 586-599.	7.3	29
34	Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?. Digestive Surgery, 2018, 35, 104-110.	1.2	4
35	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Journal of the Formosan Medical Association, 2018, 117, 381-403.	1.7	92
36	Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiotherapy and Oncology, 2018, 126, 368-374.	0.6	29

#	Article	IF	CITATIONS
37	Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. Anticancer Research, 2018, 38, 1569-1577.	1.1	9
38	A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement. Journal of the Formosan Medical Association, 2017, 116, 689-696.	1.7	9
39	Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer, 2017, 6, 264-274.	7.7	46
40	Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation. Oncotarget, 2017, 8, 101832-101846.	1.8	9
41	Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation. Asian Journal of Andrology, 2017, 19, 596.	1.6	3
42	A phase II study of early FDG-PET evaluation after one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy: Final report Journal of Clinical Oncology, 2017, 35, 4042-4042.	1.6	14
43	MicroRNA-146a-5p Negatively Regulates Pro-Inflammatory Cytokine Secretion and Cell Activation in Lipopolysaccharide Stimulated Human Hepatic Stellate Cells through Inhibition of Toll-Like Receptor 4 Signaling Pathways. International Journal of Molecular Sciences, 2016, 17, 1076.	4.1	48
44	The ratio of weight loss to planning target volume significantly impacts setup errors in nasopharyngeal cancer patients undergoing helical tomotherapy with daily megavoltage computed tomography. Radiology and Oncology, 2016, 50, 427-432.	1.7	12
45	Radiosensitization in esophageal squamous cell carcinoma. Strahlentherapie Und Onkologie, 2016, 192, 260-268.	2.0	8
46	Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. Chronobiology International, 2016, 33, 210-219.	2.0	33
47	How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver Cancer, 2016, 5, 210-220.	7.7	14
48	Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer. Case Reports in Oncology, 2016, 9, 474-480.	0.7	2
49	Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer, 2016, 5, 162-174.	7.7	53
50	Gastrointestinal Cancers—Changing the Standard forÂRectal Cancer and Establishing a New Standard forÂLiverÂTumors. International Journal of Radiation Oncology Biology Physics, 2016, 95, 930-936.	0.8	1
51	Dual-timing PSA as a biomarker for patients with salvage intensity modulated radiation therapy for biochemical failure after radical prostatectomy. Oncotarget, 2016, 7, 44224-44235.	1.8	2
52	A Walk-and-Eat Intervention Improves Outcomes for Patients With Esophageal Cancer Undergoing Neoadjuvant Chemoradiotherapy. Oncologist, 2015, 20, 1216-1222.	3.7	63
53	The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer. World Journal of Surgical Oncology, 2015, 13, 312.	1.9	4
54	<scp>S</scp> onic <scp>H</scp> edgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1317-1324.	2.8	28

#	Article	IF	CITATIONS
55	Patterns of Nodal Metastases on 18F-FDG PET/CT in Patients With Esophageal Squamous Cell Carcinoma are Useful to Guide Treatment Planning of Radiotherapy. Clinical Nuclear Medicine, 2015, 40, 384-389.	1.3	7
56	Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation. Scientific Reports, 2015, 5, 10291.	3.3	24
57	Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2015, 10, 1481-1489.	1.1	15
58	Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer, 2015, 4, 96-105.	7.7	19
59	Randomized Trials and New Directions inÂGastrointestinal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 459-464.	0.8	3
60	Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma. Radiotherapy and Oncology, 2015, 115, 9-15.	0.6	12
61	Serum Transforming Growth Factor-Î ² 1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1023-1031.	0.8	2
62	Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells. Molecular Cancer Therapeutics, 2015, 14, 810-820.	4.1	26
63	Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity. World Journal of Surgical Oncology, 2014, 12, 329.	1.9	4
64	Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption. International Journal of Cancer, 2014, 135, 492-501.	5.1	19
65	Radiation-induced VEGF-C expression and endothelial cell proliferation in lung cancer. Strahlentherapie Und Onkologie, 2014, 190, 1154-1162.	2.0	31
66	Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. Practical Radiation Oncology, 2014, 4, 198-206.	2.1	31
67	High Serum Levels of Vascular Endothelial Growth Factor-A and Transforming Growth Factor-Î ² 1 Before Neoadjuvant Chemoradiotherapy Predict Poor Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Combined Modality Therapy. Annals of Surgical Oncology, 2014, 21, 2361-2368.	1.5	21
68	Preoperative Prognostic Neurologic Index for Glioblastoma Patients Receiving Tumor Resection. Annals of Surgical Oncology, 2014, 21, 3992-3998.	1.5	6
69	Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 661-668.	2.8	57
70	Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. Oncotarget, 2014, 5, 3662-3672.	1.8	40
71	Superior liver sparing by combined coplanar/noncoplanar volumetric-modulated arc therapy for hepatocellular carcinoma: A planning and feasibility study. Medical Dosimetry, 2013, 38, 366-371.	0.9	7
72	Pretreatment prostate specific antigen (PSA) and 2-year PSA dynamics: Early predictors of prostate cancer prognosis with external radiation therapy. Urological Science, 2013, 24, 120-123.	0.6	2

#	Article	IF	CITATIONS
73	Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. European Journal of Cancer, 2013, 49, 1458-1466.	2.8	27
74	Biomarker Studies on Radiotherapy to Hepatocellular Carcinoma. Oncology, 2013, 84, 64-68.	1.9	10
75	Comparison of tumor recurrence between laparoscopic total mesorectal excision with sphincter preservation and laparoscopic abdominoperineal resection for low rectal cancer. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 3452-3464.	2.4	12
76	Prone breast forward intensity-modulated radiotherapy for Asian women with early left breast cancer: factors for cardiac sparing and clinical outcomes. Journal of Radiation Research, 2013, 54, 899-908.	1.6	14
77	Early Detection of Lewis Lung Carcinoma Tumor Control by Irradiation Using Diffusion-Weighted and Dynamic Contrast-Enhanced MRI. PLoS ONE, 2013, 8, e62762.	2.5	9
78	Outcome analysis of cervical adenosquamous carcinoma compared with adenocarcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 1158-1166.	2.8	14
79	Postoperative Intensity-Modulated Radiotherapy for Squamous Cell Carcinoma of the External Auditory Canal and Middle Ear: Treatment Outcomes, Marginal Misses, and Perspective on Target Delineation. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1485-1493.	0.8	17
80	Radiosensitizing Effect of a Phenylbutyrate-Derived Histone Deacetylase Inhibitor in Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 83, e181-e189.	0.8	22
81	Volumetric modulated arc therapy for nasopharyngeal carcinoma: A dosimetric comparison with TomoTherapy and step-and-shoot IMRT. Radiotherapy and Oncology, 2012, 104, 324-330.	0.6	93
82	Programmable segmented volumetric modulated arc therapy for respiratory coordination in pancreatic cancer. Radiotherapy and Oncology, 2012, 104, 386-389.	0.6	0
83	Radiation therapy for primary and metastatic tumors of the liver. Journal of Radiation Oncology, 2012, 1, 227-237.	0.7	2
84	Phase-specific cone beam computed tomography reduces reconstructed volume loss of moving phantom. Strahlentherapie Und Onkologie, 2012, 188, 77-83.	2.0	2
85	Branched α-(1,4) Glucans from Lentinula edodes (L10) in Combination with Radiation Enhance Cytotoxic Effect on Human Lung Adenocarcinoma through the Toll-like Receptor 4 Mediated Induction of THP-1 Differentiation/Activation. Journal of Agricultural and Food Chemistry, 2011, 59, 11997-12005.	5.2	21
86	Polymorphism in Epidermal Growth Factor Receptor Intron 1 Predicts Prognosis of Patients with Esophageal Cancer after Chemoradiation and Surgery. Annals of Surgical Oncology, 2011, 18, 2066-2073.	1.5	22
87	Retrospective Analysis of Outcome Differences in Preoperative Concurrent Chemoradiation With or Without Elective Nodal Irradiation for Esophageal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, e593-e599.	0.8	42
88	Treatment and Dosimetric Advantages Between VMAT, IMRT, and Helical TomoTherapy in Prostate Cancer. Medical Dosimetry, 2011, 36, 264-271.	0.9	92
89	Practically acquired and modified cone-beam computed tomography images for accurate dose calculation in head and neck cancer. Strahlentherapie Und Onkologie, 2011, 187, 633-644.	2.0	12
90	Skin Dose Impact from Vacuum Immobilization Device and Carbon Fiber Couch in Intensity Modulated Radiation Therapy for Prostate Cancer. Medical Dosimetry, 2009, 34, 228-232.	0.9	18

#	Article	IF	CITATIONS
91	Radiation-Induced Interleukin-6 Expression Through MAPK/p38/NF-κB Signaling Pathway and the Resultant Antiapoptotic Effect on Endothelial Cells Through Mcl-1 Expression With sIL6-Rα. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1553-1561.	0.8	42
92	Using Cone-Beam Computed Tomography to Evaluate the Impact of Bladder Filling Status on Target Position in Prostate Radiotherapy. Strahlentherapie Und Onkologie, 2009, 185, 588-595.	2.0	31
93	Synergistic Effect of Radiation and Interleukin-6 on Hepatitis B Virus Reactivation in Liver Through STAT3 Signaling Pathway. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1545-1552.	0.8	25
94	Association of Clinical and Dosimetric Factors with Postoperative Pulmonary Complications in Esophageal Cancer Patients Receiving Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy Followed by Thoracic Esophagectomy. Annals of Surgical Oncology, 2009, 16, 1669-1677.	1.5	35
95	Mathematical estimation and in vivo dose measurement for cone-beam computed tomography on prostate cancer patients. Radiotherapy and Oncology, 2009, 92, 57-61.	0.6	19
96	Evaluation of radiation dose and positioning accuracy on X-ray volume imaging system for image-guided radiotherapy. Nuclear Instruments & Methods in Physics Research B, 2008, 266, 2203-2206.	1.4	2
97	Improved local control by surgery and paclitaxelâ€based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective nonâ€randomized study. Journal of Surgical Oncology, 2008, 98, 34-41.	1.7	28
98	Essential Dosimetric Parameters of Liver for the Association With Radiation-Induced Liver Disease and Virus Reactivation: In Regard to Kim et al. (Int J Radiat Oncol Biol Phys 2007;69:813–819). International Journal of Radiation Oncology Biology Physics, 2008, 71, 961.	0.8	2
99	Comprehensive Locoregional Treatment and Systemic Therapy for Postmastectomy Isolated Locoregional Recurrence. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1456-1464.	0.8	38
100	Radiation-Induced Hepatitis B Virus Reactivation in Liver Mediated by the Bystander Effect from Irradiated Endothelial Cells. Clinical Cancer Research, 2007, 13, 851-857.	7.0	94
101	Set-up errors due to endorectal balloon positioning in intensity modulated radiation therapy for prostate cancer. Radiotherapy and Oncology, 2007, 84, 177-184.	0.6	19
102	Should adjuvant radiotherapy to the supraclavicular fossa be routinely given in patients with breast conservative treatment?. Journal of Surgical Oncology, 2007, 96, 144-150.	1.7	12
103	Practical setup and appropriate parameters are essential for plan comparison: In regards to Ringash et al. (Int J Radiat Oncol Biol Phys 2005;63:732–738). International Journal of Radiation Oncology Biology Physics, 2006, 65, 311.	0.8	0
104	Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1150-1156.	0.8	46
105	SU-FF-T-222: The Analysis of Confounding Factors in Volume Reconstruction of 3DCRT with Spiral Mode CT Simulation. Medical Physics, 2005, 32, 2001-2001.	3.0	0
106	Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer, 2004, 101, 2126-2133.	4.1	27
107	The chance of further chemoembolization and intrahepatic disease control after radiotherapy to portal vein thrombus. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1316.	0.8	0
108	Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1502-1509.	0.8	169

#	Article	IF	CITATIONS
109	Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease. International Journal of Radiation Oncology Biology Physics, 2003, 56, 229-234.	0.8	70
110	Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1010-1018.	0.8	38
111	MODEL ANALYSIS OF RESPIRATION-RELATED DOSIMETRIC CHANGE DURING RADIOTHERAPY. Biomedical Engineering - Applications, Basis and Communications, 2002, 14, 35-39.	0.6	0
112	Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiotherapy and Oncology, 2002, 63, 41-45.	0.6	102
113	Locoregional failure of postmastectomy patients with 1–3 positive axillary lymph nodes without adjuvant radiotherapy. International Journal of Radiation Oncology Biology Physics, 2002, 52, 980-988.	0.8	61
114	Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. International Journal of Radiation Oncology Biology Physics, 2002, 53, 344-352.	0.8	38
115	Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. International Journal of Radiation Oncology Biology Physics, 2002, 54, 156-162.	0.8	158
116	Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. International Journal of Cancer, 2001, 96, 126-132.	5.1	121
117	Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. International Journal of Cancer, 2001, 96, 243-252.	5.1	56
118	Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. International Journal of Radiation Oncology Biology Physics, 2000, 47, 435-442.	0.8	157
119	Letters to the editor. International Journal of Radiation Oncology Biology Physics, 2000, 48, 909-910.	0.8	0
120	Different Dose escalation from plan normalization scheme. Radiotherapy and Oncology, 2000, 54, 284.	0.6	0
121	A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 1025-1033.	2.8	95